R33CA281918
Project Grant
Overview
Grant Description
A platform to identify in vivo targets of covalent cancer drugs in 3D tissues.
Awardee
Funding Goals
NOT APPLICABLE
Grant Program (CFDA)
Awarding / Funding Agency
Place of Performance
La Jolla,
California
920371000
United States
Geographic Scope
Single Zip Code
Related Opportunity
Analysis Notes
Amendment Since initial award the total obligations have increased 97% from $450,690 to $885,944.
Scripps Research Institute was awarded
Project Grant R33CA281918
worth $885,944
from National Cancer Institute in September 2023 with work to be completed primarily in La Jolla California United States.
The grant
has a duration of 3 years and
was awarded through assistance program 93.394 Cancer Detection and Diagnosis Research.
The Project Grant was awarded through grant opportunity Advanced Development and Validation of Emerging Molecular and Cellular Analysis Technologies for Basic and Clinical Cancer Research (R33 Clinical Trial Not Allowed).
Status
(Ongoing)
Last Modified 8/20/24
Period of Performance
9/19/23
Start Date
8/31/26
End Date
Funding Split
$885.9K
Federal Obligation
$0.0
Non-Federal Obligation
$885.9K
Total Obligated
Activity Timeline
Transaction History
Modifications to R33CA281918
Additional Detail
Award ID FAIN
R33CA281918
SAI Number
R33CA281918-3496064775
Award ID URI
SAI UNAVAILABLE
Awardee Classifications
Nonprofit With 501(c)(3) IRS Status (Other Than An Institution Of Higher Education)
Awarding Office
75NC00 NIH NATIONAL CANCER INSTITUTE
Funding Office
75NC00 NIH NATIONAL CANCER INSTITUTE
Awardee UEI
PHZJFZ32NKH4
Awardee CAGE
08PA3
Performance District
CA-50
Senators
Dianne Feinstein
Alejandro Padilla
Alejandro Padilla
Budget Funding
Federal Account | Budget Subfunction | Object Class | Total | Percentage |
---|---|---|---|---|
National Cancer Institute, National Institutes of Health, Health and Human Services (075-0849) | Health research and training | Grants, subsidies, and contributions (41.0) | $450,690 | 100% |
Modified: 8/20/24